Alliance Global Partners Lowers DarioHealth (NASDAQ:DRIO) Price Target to $7.50

DarioHealth (NASDAQ:DRIOGet Rating) had its price target cut by Alliance Global Partners from $9.15 to $7.50 in a research note published on Wednesday, The Fly reports. They currently have a buy rating on the stock.

A number of other brokerages have also weighed in on DRIO. Cowen decreased their target price on DarioHealth from $18.00 to $14.00 and set an outperform rating on the stock in a research note on Tuesday, August 16th. Aegis decreased their target price on DarioHealth from $20.00 to $15.00 and set a buy rating on the stock in a research note on Thursday, August 18th. Finally, Cowen decreased their target price on DarioHealth from $18.00 to $14.00 and set an outperform rating on the stock in a research note on Tuesday, August 16th.

DarioHealth Price Performance

Shares of NASDAQ DRIO opened at $5.11 on Wednesday. The firm has a market capitalization of $119.06 million, a P/E ratio of -1.59 and a beta of 1.16. The company has a quick ratio of 5.71, a current ratio of 6.21 and a debt-to-equity ratio of 0.27. The stock’s 50-day simple moving average is $4.45 and its two-hundred day simple moving average is $5.37. DarioHealth has a twelve month low of $3.66 and a twelve month high of $17.05.

Hedge Funds Weigh In On DarioHealth

Several institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in shares of DarioHealth by 7.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 36,948 shares of the company’s stock valued at $216,000 after purchasing an additional 2,712 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in DarioHealth during the 1st quarter valued at about $25,000. FMR LLC boosted its holdings in DarioHealth by 1,268.0% during the 2nd quarter. FMR LLC now owns 5,650 shares of the company’s stock valued at $35,000 after acquiring an additional 5,237 shares during the period. State Street Corp boosted its holdings in DarioHealth by 2.9% during the 1st quarter. State Street Corp now owns 333,544 shares of the company’s stock valued at $1,948,000 after acquiring an additional 9,301 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in DarioHealth by 5.4% during the 1st quarter. Vanguard Group Inc. now owns 272,997 shares of the company’s stock valued at $1,594,000 after acquiring an additional 14,033 shares during the period. 46.50% of the stock is currently owned by institutional investors.

About DarioHealth

(Get Rating)

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.

Read More

The Fly logo

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.